Parkinson's disease.
In Parkinson's disease there is degeneration of neurons in the substantia nigra, with consequent depletion of the neurotransmitter dopamine. The triad of tremor, rigidity and bradykinesia is the clinical hallmark. Drugs currently used for palliative therapy fall into three categories: anticholinergic agents, dopamine precursors (levodopa combined with extracerebral decarboxylase inhibitors) and artificial dopamine agonists. It has been argued, on theoretical grounds, that some drugs slow the progress of Parkinson's disease, although no firm evidence has supported this. Treatment must be individualized, and more than one type of drug can be given concurrently after a careful build-up in dosage. We review the adverse effects of various drugs and consider new developments such as slow-release preparations, selective D-1 and D-2 agonists and transplants of dopaminergic cells into the brain. The treatment of Parkinson's disease can be demanding, rewarding and sometimes frustrating, but it remains a most challenging exercise in pharmacotherapy.
Wolters
E C
EC
Department of Medicine, University Hospital, Vancouver, BC.
Calne
D B
DB
D000311:Adrenal Glands / Q000637:transplantation; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use; D002421:Caudate Nucleus; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000628:therapy; D011379:Prognosis
D000975:Antioxidants; D015259:Dopamine Agents; D010276:Parasympatholytics; D007980:Levodopa